Evidence map›Paper›PMID 23022358›Full record

ReviewExperimental and molecular pathology2012

Reversion of the ErbB malignant phenotype and the DNA damage response.

E Aaron Runkle, Hongtao Zhang, Zheng Cai, Zhiqiang Zhu, Barry L Karger, Shiaw-Lin Wu, Donald M O'Rourke, Zhaocai Zhou, Qiang Wang, Mark I Greene

Abstract readReview
In one paragraph

Review in Experimental and molecular pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

E Aaron RunkleDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Hongtao Zhang
Zheng Cai
Zhiqiang Zhu
Barry L Karger
Shiaw-Lin Wu
Donald M O'Rourke
Zhaocai Zhou
Qiang Wang
Mark I Greene

Funding

IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1M
RECEPTOR MEDIATED BREAST CANCER THERAPYR01CA089481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GREENE, MARK I · 2001 to 2015
$3.3M
IMMUNOBIOLOGY OF P185 RECEPTORR01CA055306 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GREENE, MARK I · 1992 to 2011
$2.6M
NCI NIH HHS 5R01 CA055306-17NCI NIH HHS CA089481-10NCI NIH HHS R01 CA055306NCI NIH HHS R01 CA089481NCI NIH HHS T32 CA009140
6 · The paper itself

Abstract

The ErbB or HER family is a group of membrane bound tyrosine kinase receptors that initiate signal transduction cascades, which are critical to a wide range of biological processes. When over-expressed or mutated, members of this kinase family form homomeric or heteromeric kinase assemblies that are involved in certain human malignancies. Targeted therapy evolved from studies showing that monoclonal antibodies to the ectodomain of ErbB2/neu would reverse the malignant phenotype. Unfortunately, tumors develop resistance to targeted therapies even when coupled with genotoxic insults such as radiation. Radiation treatment predominantly induces double strand DNA breaks, which, if not repaired, are potentially lethal to the cell. Some tumors are resistant to radiation treatment because they effectively repair double strand breaks. We and others have shown that even in the presence of ionizing radiation, active ErbB kinase signaling apparently enhances the repair process, such that transformed cells resist genotoxic signal induced cell death. We review here the current understanding of ErbB signaling and DNA double strand break repair. Some studies have identified a mechanism by which DNA damage is coordinated to assemblies of proteins that associate with SUN domain containing proteins. These assemblies represent a new target for therapy of resistant tumor cells.

Indexed as

DNA DamageDNA, NeoplasmDNA RepairHumansIntracellular Signaling Peptides and ProteinsOncogene Proteins v-erbBPhenotypeRadiation ToleranceSignal TransductionTumor Cells, CulturedDNA, NeoplasmIntracellular Signaling Peptides and ProteinsOncogene Proteins v-erbB

Identifiers

PMID23022358
PMCPMC3518600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.